David S Schrump, M.D.

Trials

Studies that name David S Schrump, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:14 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06694454 · Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

  National Cancer Institute (NCI) · suspended · Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma · principal investigator
• Ph2
  NCT06654050 · Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

  National Cancer Institute (NCI) · withdrawn · Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma · principal investigator
• Ph2
  NCT05960773 · Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

  National Cancer Institute (NCI) · recruiting · Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma · principal investigator
• Ph1/Ph2
  NCT05898828 · Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

  National Cancer Institute (NCI) · withdrawn · Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm · principal investigator
• Ph1/Ph2
  NCT05642195 · Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

  National Cancer Institute (NCI) · suspended · Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung · principal investigator
• Ph1
  NCT05375825 · Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

  National Cancer Institute (NCI) · withdrawn · Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant · principal investigator
• Ph1/Ph2
  NCT04648826 · Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

  National Cancer Institute (NCI) · withdrawn · Sarcomas, Melanomas, Germ Cell Tumors · principal investigator
• N/A
  NCT04431024 · Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

  National Cancer Institute (NCI) · recruiting · Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS) · principal investigator
• Ph1/Ph2
  NCT03233724 · Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

  National Cancer Institute (NCI) · terminated · Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer · principal investigator
• Ph1/Ph2
  NCT02859415 · Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

  National Cancer Institute (NCI) · terminated · Esophageal Neoplasms, Lung Neoplasms, Mesothelioma · principal investigator
• Ph1
  NCT02839694 · Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

  National Cancer Institute (NCI) · withdrawn · Neoplasm Metastasis, Sarcoma, Neoplasms, Germ Cell and Embryonal · principal investigator
• Ph1/Ph2
  NCT02054104 · Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

  National Cancer Institute (NCI) · terminated · Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura · principal investigator
• Ph2
  NCT01624090 · Mithramycin for Lung, Esophagus, and Other Chest Cancers

  National Cancer Institute (NCI) · terminated · Lung Cancer, Esophageal Cancer, Mesothelioma · principal investigator
• Ph1
  NCT01341496 · Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

  National Cancer Institute (NCI) · terminated · Sarcoma, Melanoma, Epithelial Malignancies · principal investigator
• Ph1
  NCT01313429 · Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

  National Cancer Institute (NCI) · terminated · Sarcoma, Melanoma, Epithelial Malignancies · principal investigator
• Ph1
  NCT01258868 · Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

  National Cancer Institute (NCI) · terminated · Mesolthelioma, Esophageal Cancer, Lung Cancer · principal investigator
• Ph2
  NCT01160445 · Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

  National Cancer Institute (NCI) · terminated · Metastatic Melanoma, Metastatic Renal Cancer · principal investigator
• Ph1
  NCT01143545 · Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

  National Cancer Institute (NCI) · terminated · Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma · principal investigator
• N/A
  NCT00242723 · Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

  National Cancer Institute (NCI) · recruiting · Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS · principal investigator
• Ph1
  NCT00094978 · Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

  National Cancer Institute (NCI) · terminated · Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms · principal investigator
• Ph1
  NCT00037817 · Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

  National Cancer Institute (NCI) · completed · Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.